


# Infectious Disease Journal Club - Bacteria



1


## *Streptococcus equi* subsp. *equi*



## Clostridial enteritis

Common species:

- *C. perfringens* type A
- *C. perfringens* type C
- *C. difficile*




## Salmonellosis



## *Rhodococcus equi*

- Gram positive aerobic coccobacillus
- Young foals worldwide
- Immunosuppressed adult horses
- Immunosuppressed humans
- Infected early in life




2

# *Streptococcus equi* subsp. *equi*




3

## Pathogenesis



4



5

## RESEARCH ARTICLE


# Differences in the genome, methylome, and transcriptome do not differentiate isolates of *Streptococcus equi* subsp. *equi* from horses with acute clinical signs from isolates of inapparent carriers

Ellen Ruth A. Morris<sup>1</sup>, Ashley G. Boyle<sup>2</sup>, Miia Riihimäki<sup>3</sup>, Anna Aspán<sup>3</sup>, Eman Anis<sup>4</sup>, Andrew E. Hillhouse<sup>5,6</sup>, Ivan Ivanov<sup>7</sup>, Angela I. Bordin<sup>1</sup>, John Pringle<sup>3</sup>, Noah D. Cohen<sup>1\*</sup>

PLOS ONE | <https://doi.org/10.1371/journal.pone.0252804> June 14, 2021

6

## Are convalescing horses and their healthy contacts infectious?



7

## Markers of long term silent carriers of *Streptococcus equi* ssp. *equi* in horses

John Pringle<sup>1</sup>  | Monica Venner<sup>2</sup> | Lisa Tscheschlok<sup>2</sup> | Andrew S. Waller<sup>3</sup> | Miia Riihimäki<sup>1</sup>

*J Vet Intern Med.* 2020;34:2751–2757.

## Failure of serological testing for antigens A and C of *Streptococcus equi* subspecies *equi* to identify guttural pouch carriers

Andy E. Durham<sup>1</sup>  | Jeremy Kemp-Symonds<sup>2</sup>

*Equine Vet J.* 2021;53:38–43.

8

## Clostridial enteritis

Common species:

- *C. perfringens* type A
- *C. perfringens* type C
- *C. difficile*



9

## Types of Toxins

- **Exotoxin:** soluble toxin, secreted by a micro-organism, which can damage the host by destroying cells or disrupting cell metabolism
- **Cytotoxin:** any substance that has a toxic effect on cells
- **Enterotoxin:** a cytotoxin specific for the cells of the gastrointestinal tract

10

## *Clostridium perfringens*

- Five types, designated A to E
- At least 5 major toxins
  - Alpha
  - Beta
  - Epsilon
  - Iota
  - Enterotoxin (CPE)

Type	TOXINS					
	Alpha	Beta	Epsilon	Iota	Beta-2	Enterotoxin
<b>A</b>	<b>X</b>				±	±
B	X	X	X		±	±
<b>C</b>	<b>X</b>	<b>X</b>			±	±
D	X		X		±	±
E	X			X	±	±

11

## Pathogenesis: *C. perfringens*

- Toxins may be trypsin sensitive
- Antiprotease activity in colostrum/milk may prevent inactivation of toxins
- Disease appears to be more prevalent in foals with good passive transfer



12

## *Clostridium difficile*

- Produces at least 5 toxins
- Toxin A: enterotoxin
- Toxin B: cytotoxin

**Toxin A (enterotoxin):**  
increases permeability,  
chemotaxin

**Toxin B (cytotoxin):**  
cytotoxic to mucosal  
epithelium, exacerbates  
inflammatory response

13

Contents lists available at ScienceDirect

**Anaerobe**

ELSEVIER journal homepage: [www.elsevier.com/locate/anaerobe](http://www.elsevier.com/locate/anaerobe)

*Clostridium difficile*

Reclassification of *Clostridium difficile* as *Clostridioides difficile* (Hall and O'Toole 1935) Prévot 1938

Paul A. Lawson<sup>a,\*</sup>, Diane M. Citron<sup>b</sup>, Kerin L. Tyrrell<sup>b</sup>, Sydney M. Finegold<sup>c,d,e</sup>

<sup>a</sup> Department of Microbiology and Plant Biology, University of Oklahoma, Norman, USA  
<sup>b</sup> R. M. Aiken Research Laboratory, Culver City, CA, 90230, USA  
<sup>c</sup> Infectious Diseases Section, VA Medical Center West Los Angeles, 90073, USA  
<sup>d</sup> Department of Medicine, The David Geffen School of Medicine at the University of California, Los Angeles, CA, USA  
<sup>e</sup> Department of Microbiology, Immunology, and Molecular Genetics, The David Geffen School of Medicine at the University of California, Los Angeles, CA, USA

**Anaerobe 40 (2016) 95–99**

14

## NetF-producing *Clostridium perfringens* and its associated diseases in dogs and foals

Journal of Veterinary Diagnostic Investigation  
2020, Vol. 32(2) 230-238  
© 2020 The Author(s)  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/1040638720904714  
jvdi.sagepub.com

Iman Mehdizadeh Gohari,<sup>1</sup>  Stefan Unterer, Ashley E. Whitehead,   
John F. Prescott

## NetF-positive *Clostridium perfringens* in neonatal foal necrotising enteritis in Kentucky

Veterinary Record (2016)

doi: 10.1136/vr.103606

I. Mehdizadeh Gohari, V. R. Parreira,  
J. F. Timoney, L. Fallon, N. Slovis,  
J. F. Prescott

15

## Fecal PCR testing for detection of *Clostridium perfringens* and *Clostridioides difficile* toxin genes and other pathogens in foals with diarrhea: 28 cases

Journal of Veterinary Diagnostic Investigation  
2022, Vol. 34(3) 396-401  
© 2021 The Author(s)  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/10406387211047529  
jvdi.sagepub.com

K. Gary Magdesian,<sup>1</sup>  Samantha Barnum, Nicola Pusterla

Foals < 30 days of age with diarrhea between 2017- 2020

Foal diarrhea PCR panel performed

Looked at results from all foals testing positive for clostridial disease

16

**Table 3.** Comparison of age and clinical pathology data between foals with clostridial and “other” diarrhea.

	Unit	Clostridial group	Other group	<i>p</i>
Age	d	2 (0.5–20)	12 (2–27)	0.0029
Eosinophils	×10 <sup>9</sup> /L	0.00 (0.00–0.07)	0.02 (0.06–1.22)	0.03
Hematocrit	L/L	0.39±0.05	0.32±0.08	0.0087
Hemoglobin	g/L	135±16	110±26	0.0067
Red blood cells	×10 <sup>12</sup> /L	9.83±1.35	8.23±2.07	0.028
Total protein	g/L	53±5	59±9	0.045

Foals with  
clostridial  
diarrhea:

Younger

More  
hemocon-  
centration

Lower  
plasma  
protein

More band  
neutrophils

13/14 foals with clostridial  
diarrhea had IgG > 800  
mg/dL

17

Received: 14 October 2020 | Accepted: 19 February 2021  
DOI: 10.1111/jvim.16094

STANDARD ARTICLE

Journal of Veterinary Internal Medicine **ACVIM**  
Open Access American College of  
Veterinary Internal Medicine


## *Clostridioides (Clostridium) difficile* in neonatal foals and mares at a referral hospital

Jeffrey Scott Weese<sup>1</sup> | Nathan Slovis<sup>2</sup> | Joyce Rousseau<sup>1</sup>

Foals admitted to the NICU in 2017 *without suspected infectious diarrhea or any other suspected infectious disease* were included. Rectal swabs were obtained from the mare and the foal approximately every 3 days and samples were cultured for *C. difficile*. Isolates were characterized by toxin gene PCR and ribotyping. A total of 97 mare-foal pairs and 16 unaccompanied foals from 76 farms were enrolled (113 foals and 97 mares).

18

Both negative, 56



**FIGURE 2** *C. difficile* shedding status of 97 mare-foal pairs at admission to an equine referral hospital

15 foals had 2 positive samples during hospitalization. In only 6/15 was the same strain identified both times.

"These findings suggest that *C. difficile* shedding is variable, sporadic, and dynamic in horses, rather than a situation in which a strain colonizes the gastrointestinal tract and persists."

19

# Salmonellosis



20

## Widespread Environmental Presence of Multidrug-Resistant *Salmonella* in an Equine Veterinary Hospital That Received Local and International Horses

Paula Soza-Ossandón<sup>1</sup>, Dácil Rivera<sup>1,2</sup>, Rodolfo Tardone<sup>1</sup>, Roberto Riquelme-Neira<sup>1,2</sup>, Patricia García<sup>2,3</sup>, Christopher Hamilton-West<sup>4</sup>, Aiko D. Adell<sup>1,2</sup>, Gerardo González-Rocha<sup>2,5</sup> and Andrea I. Moreno-Switt<sup>1,2,6\*</sup>

<sup>1</sup> Escuela de Medicina Veterinaria, Facultad de Ciencias de la Vida, Universidad Andres Bello, Santiago, Chile, <sup>2</sup> Millennium Initiative for Collaborative Research on Bacterial Resistance (MICROB-R), Santiago, Chile, <sup>3</sup> Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, <sup>4</sup> Unidad de Epidemiología Veterinaria, Departamento Medicina Preventiva Animal, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile, <sup>5</sup> Laboratorio de Investigación de Agentes Antimicrobianos, Departamento de Microbiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile, <sup>6</sup> Escuela de Medicina Veterinaria, Pontificia Universidad Católica de Chile, Santiago, Chile



BRIEF RESEARCH REPORT  
published: 10 July 2020  
doi: 10.3389/fvets.2020.00346

Collected 545 samples from the environment and from hospitalized patients with monthly sampling over a 1-year period. Isolates were tested for antimicrobial resistance, serotype, and molecular typing via pulsed-field gel electrophoresis. This racetrack-based hospital had numerous local and international horses as patients during that time. **No disease outbreaks or hospital-acquired infections due to *Salmonella* occurred in this time.**

21

**TABLE 1 |** Results of *Salmonella* spp. on samples collected in the equine veterinary hospital during the study.

Sample origin	No. of samples	No. positive samples	% positive samples
Animal feces	53	1	1.88
<b>Environmental/surgery (SA)<sup>a</sup></b>			
Stalls (1–4)	48	1	2.08
Surgery room floor	12	2	16.67
Bed	12	0	0
Pharmacy	12	1	8.33
Washing room	12	1	8.33
Dressing room	12	0	0
Personal entrance	12	0	0
Office	12	0	0
Induction/recovery room	12	0	0
Area Floor	12	0	0
<b>Environmental/hospitalization (HA)<sup>a</sup></b>			
Stalls (5–10)	72	3	4.17
Floor	12	1	8.33
<b>Environmental/proceeding (PA)<sup>a</sup></b>			
Pharmacy	12	1	8.33
Floor	12	1	8.33
Main office	12	2 <sup>b</sup>	16.67
<b>Environmental/equipment (EQ)<sup>a</sup></b>			
Twitches (3x)	36	1	2.78
Endoscope	12	1	8.33
Gastroscope	12	1	8.33
Pitchforks (2x)	24	2	8.33
Waterers (1x)	120	1	0.83
<b>Environmental/external (EA)<sup>a</sup></b>			
Manure collection site	12	1	8.33
<b>Total</b>	<b>545</b>	<b>21</b>	<b>3.85</b>

Overall, 21 of 545 samples (3.9%) were positive. The one isolate from feces came from a colic patient. The highest number of samples were obtained in spring (September) and winter (June).

Multiple PFGE and antimicrobial resistance patterns were observed. Most isolates were multidrug resistant. Positive samples were obtained primarily from human contact surfaces. Numerous positive samples came from equipment.

22



23

Hindawi  
Case Reports in Veterinary Medicine  
Volume 2020, Article ID 7062408, 5 pages  
<https://doi.org/10.1155/2020/7062408>

### Case Report

## Atypical *Salmonellosis* in a Horse: Implications for Hospital Safety

Kristina L. Rothers,<sup>1</sup> Eileen S. Hackett,<sup>1</sup> Gary L. Mason,<sup>2</sup> and Brad B. Nelson<sup>1</sup>

<sup>1</sup>Department of Clinical Sciences, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523, USA  
<sup>2</sup>Veterinary Diagnostic Laboratory, Colorado State University, 300 West Lake Road, Fort Collins, CO 80523, USA

A 17-year-old Quarter Horse mare was treated for duodenitis-proximal jejunitis (fever, nasogastric reflux, colic). The horse was euthanized. Aerobic culture of jejunal contents yielded *Salmonella enterica* serovar Hadar. This mare had produced large volumes of gastric reflux during hospitalization. What was the risk to individuals who treated this mare?



24



Online survey conducted in April 2019.

- Gender, years in practice?
- Do you use your mouth?
- Have you ever swallowed stomach contents?
- Have you ever aspirated stomach contents?
- Have you had a medical problem after intubation of a horse?
- Use mouth with suspect poisoning?
- Use mouth with fever, reflux, diarrhea?
- Wash, disinfect, or sterilize after each use?

25



Medical issues related to nasogastric intubation included 4 respondents with cough (1 with pneumonia, 1 with fever), 3 respondents with diarrhea (1 diagnosed with salmonellosis), and 1 hospitalized after zinc phosphide inhalation.

Four respondents mentioned ascarids coming from the tube or into their mouth. One respondent mentioned a colleague with MRSA infection associated with intubation.



26

## *Rhodococcus equi*

- Gram positive aerobic coccobacillus
- Young foals worldwide
- Immunosuppressed adult horses
- Immunosuppressed humans
- Infected early in life



27



28

American Society for Microbiology  
 Antimicrobial Agents and Chemotherapy  
 Volume 63, Issue 1, January 2019  
<https://doi.org/10.1128/AAC.01714-18>


Epidemiology and Surveillance

## Emergence of Resistance to Macrolides and Rifampin in Clinical Isolates of *Rhodococcus equi* from Foals in Central Kentucky, 1995 to 2017

Laura Huber<sup>a</sup>, Steeve Giguère<sup>a</sup>, Nathan M. Slovis<sup>b</sup>, Craig N. Carter<sup>c</sup>, Bonnie S. Barr<sup>d</sup>, Noah D. Cohen<sup>e</sup>, Justine Elam<sup>b</sup>, Erdal Erol<sup>c</sup>, Stephan J. Locke<sup>c</sup>, Erica D. Phillips<sup>c</sup>, and Jacqueline L. Smith<sup>c</sup>

farm

29



30

## Association between antimicrobial treatment of subclinical pneumonia in foals and selection of macrolide- and rifampicin-resistant *Rhodococcus equi* strains at horse-breeding farms in central Kentucky

JAVMA | MAR 15, 2021 | VOL 258 | NO. 6


Laura Huber DVM, MSc  
 Steeve Giguère DVM, PhD†  
 Kelsey A. Hart DVM, PhD  
 Nathan M. Slovis DVM  
 Maggie E. Greiter BS  
 Cody A. Dailey MPH  
 Noah D. Cohen VMD, MPH, PhD

10 farms with 5-year history of ultrasound and treatment

10 farms that didn't use ultrasound screening

Data from 2019 foaling season

31



32

### Journal of the American Veterinary Medical Association

July 1, 2010, Vol. 237, No. 1, Pages 74-81

<https://doi.org/10.2460/javma.237.1.74>

#### Determination of the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in *Rhodococcus equi* isolates and treatment outcome in foals infected with antimicrobial-resistant isolates of *R equi*

Steeve Giguère, DVM, PhD, DACVIM; Elise Lee, BS; Elliott Williams, BS; Noah D. Cohen, VMD, PhD, DACVIM; M. Keith Chaffin, DVM, MS, DACVIM; Natalie Halbert, PhD; Ronald J. Martens, DVM; Robert P. Franklin, DVM, DACVIM; Carol C. Clark, DVM, DACVIM; Nathan M. Slovis, DVM, DACVIM



33

Foal	Antimicrobial resistance*	Antimicrobial treatment administered†	Treatment outcome‡
1	M and R	D + R → C + R → V + G	Dead
2	M, R, and CL	D + R → C + R → V + C + R	Survived
3	M, R, and CL	D + R → C + R → V	Survived
4	M, R, and C	A → C + R → V	Dead
5	R	A + R	Survived
6	M, R, and CL	A + R	Dead
7	M, R, and CL	A + R → C + R	Survived
8	M, R, and CL	NA	Dead
9	R	C + R	Dead
10	M, R, and CL	NA	Dead
11	M, R, and CL	C + R	Dead
12	M and R	C + R	Dead
13	M, R, and CL	A → V	Survived
14	M, R, and CL	C + R → D → V	Dead
15	M, R, and CL	C + R → D + R	Survived
16	M, R, and CL	NA	Dead
17	M, R, and CL	A + R → C + R → D + R	Dead
18	M, R, and CL	A + R	Survived
19	M, R, and CL	NA	Dead

A = Azithromycin. C = Clarithromycin. CL = Clindamycin. D = Doxycycline. G = Gentamicin. M = Macrolide antimicrobials. NA = Not available. R = Rifampin. V = Vancomycin.

34

## Changing policy to treat foals with *Rhodococcus equi* pneumonia in the later course of disease decreases antimicrobial usage without increasing mortality rate

Denise Arnold-Lehna<sup>1</sup>  | Monica Venner<sup>2</sup>  | Londa J. Berghaus<sup>3</sup>  | Roy Berghaus<sup>4</sup>  |  
Steeve Giguère<sup>3</sup> 

*Equine Vet J.* 2020;52:531–537.

330 foals per year with pneumonia

Weekly physical exam, CBC, thoracic ultrasound

2008 to 2011: every foal with pulmonary abscesses was treated

2012 to 2016: only foals with severe abscesses were treated

35

**TABLE 2** Comparison of outcome variables between the two time periods (all foals included)

Variables	2008-2011 (n = 1215)	2012-2016 (n = 1541)	P
Treated for pneumonia (%)	81.9	50.9	<.001
Total duration of antimicrobial therapy (d) <sup>a</sup>	41 (0-93) <sup>b</sup>	23 (0-53)	<.001
Death from pneumonia or <i>R equi</i> infection (%) <sup>c</sup>	0.41	0.58	.593
Death from all causes (%)	1.15	1.65	.333

<sup>a</sup>Duration of therapy entered as 0 for foals that were not treated.

<sup>b</sup>Median (5th and 95th percentiles).

<sup>c</sup>Also includes death from extrapulmonary infections caused by *R equi*.

36

# Prevention

- Hyperimmune plasma
- Does **NOT** prevent infection
- Ultrasound evidence of infection
- Product variability



37

## *Rhodococcus equi* hyperimmune plasma decreases pneumonia severity after a randomised experimental challenge of neonatal foals

March 12, 2016 | [Veterinary Record](#)

M. G. Sanz, A. Loynachan, D. W. Horohov


9 foals received hyperimmune plasma at 1 – 2 days of age

9 foals were untreated

All foals challenged with intratracheal inoculation of *R. equi*

Monitored for 8 weeks

38



39

## Transfusion With 2 L of Hyperimmune Plasma is Superior to Transfusion of 1 L or Less for Protecting Foals Against Subclinical Pneumonia Attributed to *Rhodococcus equi*

Journal of Equine Veterinary Science 79 (2019) 54–58

Susanne K. Kahn<sup>a</sup>, Glenn P. Blodgett<sup>b</sup>, Nathan M. Canaday<sup>b</sup>, Kari E. Bevevino<sup>a</sup>,  
Joana N. Rocha<sup>a</sup>, Angela I. Bordin<sup>a</sup>, Noah D. Cohen<sup>a,\*</sup>

<sup>a</sup> Equine Infectious Disease Laboratory, Department of Large Animal Clinical Sciences, Texas A&M University, College Station, TX

<sup>b</sup> 6666 Ranch, Guthrie, TX

Retrospective cohort study on a single farm

85 foals received 1 liter HIP

62 foals received 2 liters HIP

US at 5, 7 and 9 weeks

32% vs 12% subclinical pneumonia

40